![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Vilaprisan.svg/640px-Vilaprisan.svg.png&w=640&q=50)
Vilaprisan
Chemical compound / From Wikipedia, the free encyclopedia
Vilaprisan (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name) (developmental code name BAY-1002670) is a synthetic and steroidal selective progesterone receptor modulator (SPRM) which is under development by Bayer HealthCare Pharmaceuticals for the treatment of endometriosis and uterine fibroids.[1][2][3] It is a potent and highly selective partial agonist of the progesterone receptor (PR).[4][2][3] As of 2017, the drug is in phase II clinical trials for the aforementioned indications.[1]
Quick Facts Clinical data, Other names ...
![]() | |
Clinical data | |
---|---|
Other names | BAY-1002670; 17β-Hydroxy-11β-[4-(methylsulfonyl)phenyl]-17α-(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one |
Routes of administration | By mouth |
Drug class | Selective progesterone receptor modulator |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H29F5O4S |
Molar mass | 544.58 g·mol−1 |
3D model (JSmol) | |
| |
|
Close